Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CYRX CryoPort	$15.37 -4.1%	$15.29	$6.69 ▼ $16.89	$774.68M	1.88	746,387 shs	589,824 shs
IDYA IDEAYA Biosciences	$35.40 -2.3%	$32.98	$22.09 ▼ $40.58	$3.11B	-0.09	1.11 million shs	901,710 shs
IRON Disc Medicine	$74.12 -2.3%	$71.79	$40.00 ▼ $99.50	$2.83B	0.97	646,682 shs	403,318 shs
RGC Regencell Bioscience	$5.72 +1.8%	$14.09	$4.51 ▼ $69.00	$2.83B	1.84	556,724 shs	161,333 shs

The Best Nuclear Energy Stocks to Buy

Nuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead. This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CYRX CryoPort	0.00%	-6.90%	-3.21%	+45.14%	+96.80%
IDYA IDEAYA Biosciences	0.00%	-1.69%	-2.45%	+15.20%	+49.81%
IRON Disc Medicine	0.00%	-2.67%	+5.64%	+7.65%	+21.63%
RGC Regencell Bioscience	0.00%	+13.94%	-23.63%	-79.19%	-61.33%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CYRX CryoPort	$15.37 -4.1%	$15.29	$6.69 ▼ $16.89	$774.68M	1.88	746,387 shs	589,824 shs
IDYA IDEAYA Biosciences	$35.40 -2.3%	$32.98	$22.09 ▼ $40.58	$3.11B	-0.09	1.11 million shs	901,710 shs
IRON Disc Medicine	$74.12 -2.3%	$71.79	$40.00 ▼ $99.50	$2.83B	0.97	646,682 shs	403,318 shs
RGC Regencell Bioscience	$5.72 +1.8%	$14.09	$4.51 ▼ $69.00	$2.83B	1.84	556,724 shs	161,333 shs

The Best Nuclear Energy Stocks to Buy

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CYRX CryoPort	0.00%	-6.90%	-3.21%	+45.14%	+96.80%
IDYA IDEAYA Biosciences	0.00%	-1.69%	-2.45%	+15.20%	+49.81%
IRON Disc Medicine	0.00%	-2.67%	+5.64%	+7.65%	+21.63%
RGC Regencell Bioscience	0.00%	+13.94%	-23.63%	-79.19%	-61.33%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
CYRX CryoPort	2.78	Moderate Buy	$16.38	6.54% Upside
IDYA IDEAYA Biosciences	2.81	Moderate Buy	$50.25	41.95% Upside
IRON Disc Medicine	2.73	Moderate Buy	$104.44	40.91% Upside
RGC Regencell Bioscience	1.00	Sell	N/A	N/A

Current Analyst Ratings Breakdown

Latest CYRX, IDYA, RGC, and IRON Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
7/24/2026	CYRX CryoPort	BTIG Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$17.00 ➝ $25.00
7/17/2026	IDYA IDEAYA Biosciences	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D-)
7/17/2026	IRON Disc Medicine	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D-)
7/7/2026	IDYA IDEAYA Biosciences	Royal Bank Of Canada Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Outperform	$53.00 ➝ $48.00
7/7/2026	IDYA IDEAYA Biosciences	Truist Financial Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Buy	$65.00 ➝ $63.00
6/24/2026	RGC Regencell Bioscience	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (E+)
6/15/2026	IRON Disc Medicine	Morgan Stanley Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Overweight	$80.00 ➝ $85.00
6/12/2026	IDYA IDEAYA Biosciences	Wedbush Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Outperform	$58.00
6/10/2026	IRON Disc Medicine	Wedbush Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Outperform	$88.00
6/8/2026	CYRX CryoPort	Jefferies Financial Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Set Price Target		$13.50
6/8/2026	CYRX CryoPort	Jefferies Financial Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Hold	$13.00

(Data available from 7/26/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
CYRX CryoPort	$176.18M	4.40	N/A	N/A	$9.19 per share	1.67
IDYA IDEAYA Biosciences	$218.71M	14.22	N/A	N/A	$11.67 per share	3.03
IRON Disc Medicine	N/A	N/A	N/A	N/A	$19.52 per share	N/A
RGC Regencell Bioscience	N/A	N/A	N/A	N/A	$0.01 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
CYRX CryoPort	$78.30M	$1.35	11.39	N/A	N/A	41.57%	-7.92%	-4.79%	8/6/2026 (Estimated)
IDYA IDEAYA Biosciences	-$113.70M	-$1.60	N/A	N/A	N/A	N/A	-14.24%	-13.09%	8/10/2026 (Estimated)
IRON Disc Medicine	-$212.18M	-$6.62	N/A	N/A	N/A	N/A	-36.94%	-33.88%	8/6/2026 (Estimated)
RGC Regencell Bioscience	-$3.58M	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Latest CYRX, IDYA, RGC, and IRON Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/10/2026	Q2 2026	IDYA IDEAYA Biosciences	-$1.0613	N/A	N/A	N/A	$8.02 million	N/A
8/6/2026	Q2 2026	CYRX CryoPort	-$0.20	N/A	N/A	N/A	$48.21 million	N/A
8/6/2026	Q2 2026	IRON Disc Medicine	-$1.7124	N/A	N/A	N/A	$1.00 million	N/A
5/8/2026	Q1 2026	RGC Regencell Bioscience	N/A	-$0.0050	N/A	-$0.0050	N/A	N/A
5/5/2026	Q1 2026	IDYA IDEAYA Biosciences	-$1.07	-$1.11	-$0.04	-$1.11	$5.04 million	$6.56 million
5/5/2026	Q1 2026	IRON Disc Medicine	-$1.6227	-$1.65	-$0.0273	-$1.65	$0.44 million	N/A
5/4/2026	Q1 2026	CYRX CryoPort	-$0.20	-$0.23	-$0.03	-$0.25	$44.86 million	$47.80 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
CYRX CryoPort	N/A	N/A	N/A	N/A	N/A
IDYA IDEAYA Biosciences	N/A	N/A	N/A	N/A	N/A
IRON Disc Medicine	N/A	N/A	N/A	N/A	N/A
RGC Regencell Bioscience	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
CYRX CryoPort	N/A	2.09	2.00
IDYA IDEAYA Biosciences	N/A	10.74	10.74
IRON Disc Medicine	0.04	24.00	24.00
RGC Regencell Bioscience	N/A	1.41	N/A

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
CYRX CryoPort	92.90%
IDYA IDEAYA Biosciences	98.29%
IRON Disc Medicine	83.70%
RGC Regencell Bioscience	0.13%

Insider Ownership

Company	Insider Ownership
CYRX CryoPort	9.50%
IDYA IDEAYA Biosciences	4.70%
IRON Disc Medicine	3.76%
RGC Regencell Bioscience	2.00%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
CYRX CryoPort	1,186	50.40 million	45.61 million	Optionable
IDYA IDEAYA Biosciences	80	87.86 million	83.73 million	Optionable
IRON Disc Medicine	30	38.16 million	36.73 million	Not Optionable
RGC Regencell Bioscience	10	494.49 million	484.60 million	N/A

CYRX, IDYA, RGC, and IRON Headlines

Recent News About These Companies

Regencell Bioscience (NASDAQ:RGC) Stock Price Down 7.2% - Time to Sell?

July 22, 2026 | marketbeat.com

Regencell Bioscience (NASDAQ:RGC) Trading 12% Higher - Should You Buy?

July 21, 2026 | marketbeat.com

Regencell Bioscience (NASDAQ:RGC) Lowered to Sell Rating by Wall Street Zen

July 18, 2026 | americanbankingnews.com

Regencell Bioscience Posts Higher Losses in First-Half 2026 Results Filed on Form 6-K

July 3, 2026 | theglobeandmail.com

Regencell Bioscience surges on apparent short squeeze

July 1, 2026 | msn.com

Regencell Bioscience Holdings Limited (NASDAQ: RGC) Investors Have Until June 23, 2026 to Seek a Leadership Role in the Securities Class Action Lawsuit Contact Kaplan Fox ...

June 30, 2026 | theglobeandmail.com

Pomerantz Law Firm Announces the Filing of a Class Action Against Regencell Bioscience Holdings Limitedand Certain Officers – RGC

June 23, 2026 | globenewswire.com

Bronstein, Gewirtz & Grossman LLC Urges Regencell Bioscience Holdings Ltd. Investors to Act: Class Action Filed Alleging Investor Harm

June 23, 2026 | prnewswire.com

Regencell Deadline Today: Rosen Law Firm Urges Regencell Bioscience Holdings Limited (NASDAQ: RGC) Stockholders with Large Losses to Contact the Firm for Information About Their Rights

June 23, 2026 | businesswire.com

Portnoy Law Firm Announces Class Action on Behalf of Regencell Bioscience Holdings Limited Investors

June 23, 2026 | globenewswire.com

RGC Shareholder Alert: June 23, 2026 Lead Plaintiff Deadline in Regencell Bioscience Holdings Limited Securities Class Action - Contact The Gross Law Firm

June 23, 2026 | prnewswire.com

RGC FINAL DEADLINE ALERT: Faruqi & Faruqi, LLP Reminds Regencell Bioscience (RGC) Investors of Securities Class Action Lawsuit Deadline on June 23, 2026

June 23, 2026 | tmcnet.com

RGC Deadline: RGC Investors with Losses in Excess of $100K Have Opportunity to Lead Regencell Bioscience Holdings Limited Securities Fraud Lawsuit

June 23, 2026 | prnewswire.com

Deadline Soon: Regencell Bioscience Holdings Limited (RGC) Shareholders Who Lost Money Urged To Contact The Law Offices of Frank R. Cruz About Securities Fraud Lawsuit

June 22, 2026 | tmcnet.com

REGENCELL DEADLINE JUNE 23rd: Bragar Eagel & Squire, P.C. Urgently Reminds Regencell Bioscience Holdings Limited Investors They Have Until June 23rd to Contact the Firm Seeking Lead Plaintiff Role

June 22, 2026 | globenewswire.com

Deadline Soon: Regencell Bioscience Holdings Limited (RGC)Â Shareholders Who Lost Money Urged To Contact The Law Offices of Frank R. Cruz About Securities Fraud Lawsuit

June 22, 2026 | businesswire.com

DEADLINE ALERT for LKQ, RGC, and GLOB: The Law Offices of Frank R. Cruz Reminds Investors of Class Actions on Behalf of Shareholders

June 22, 2026 | globenewswire.com

Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of June 23, 2026 in Regencell Bioscience Holdings Limited Lawsuit - RGC

June 22, 2026 | globenewswire.com

REGENCELL DEADLINE: ROSEN, A LEADING LAW FIRM, Encourages Regencell Bioscience Holdings Limited ...

June 21, 2026 | gazettextra.comG

REGENCELL DEADLINE: ROSEN, A LEADING LAW FIRM, Encourages Regencell Bioscience Holdings Limited Investors with Losses in Excess of $100K to Secure Counsel Before Important June 23 Deadline in Securities Class Action – RGC

June 21, 2026 | globenewswire.com

Bronstein, Gewirtz & Grossman LLC Urges Regencell Bioscience Holdings Ltd. Investors to Act: Class Action Filed Alleging Investor Harm

June 21, 2026 | globenewswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

CYRX, IDYA, RGC, and IRON Company Descriptions

CryoPort NASDAQ:CYRX

$15.37 -0.66 (-4.12%)

Closing price 07/24/2026 04:00 PM Eastern

Extended Trading

$15.37 0.00 (0.00%)

As of 07/24/2026 07:34 PM Eastern

Cryoport, Inc. provides temperature-controlled supply chain solutions in biopharma/pharma, animal health, and human reproductive medicine markets in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. The company offers Cryoport Express Shippers; Cryoport ELITE -80°C Gene Therapy Shipper; Cryoport ELITE Cryosphere Shipper; Cryoport consulting services, including physical, thermal, and shipping qualifications of shipping systems and/or packaging to developing custom packaging solutions; and Cryoport bioservices, such as controlled temperature storage, fulfilment, kit production, secondary packaging, labelling of therapeutic products, and GMP raw materials storage services. It also provides CRYOGENE, an unparalleled solution that offers pre-clinical temperature-controlled biological materials management services comprising specimen storage, processing, collection, and retrieval; CRYOPD, a temperature-controlled logistics solution, which include temperature-controlled packaging and transport solutions from cryogenic temperature to controlled ambient; and IntegriCell services that comprise apheresis/leukapheresis collection, Cryoshuttle transportation, cryo-process optimization and processing services. In addition, the company offers MVE Biological Solutions' Fusion cryogenic system, a self-sustaining cryogenic freezer; MVE Biological Solutions' Vario cryogenic system, a cryogenic freezer system that supports temperatures between -20°C and -150°C; Cryoport Cryoshuttle provides clients with dedicated local transportation support; and Tec4Med. Further, it provides biological specimen cryopreservation storage and maintenance; archiving, monitoring, tracking, receipt, and delivery of samples; frozen biological specimens transportation; and incoming and outgoing biological specimens management; and short-term logistics and engineering consulting services. Cryoport, Inc. was founded in 1999 and is headquartered in Brentwood, Tennessee.

IDEAYA Biosciences NASDAQ:IDYA

$35.40 -0.83 (-2.29%)

Closing price 07/24/2026 04:00 PM Eastern

Extended Trading

$35.38 -0.02 (-0.04%)

As of 07/24/2026 07:34 PM Eastern

IDEAYA Biosciences, Inc., a synthetic lethality-focused precision medicine oncology company, discovers and develops targeted therapeutics for patient populations selected using molecular diagnostics in the United States. The company's products in development include IDE196, a protein kinase C inhibitor that is in Phase 2/3 clinical trials for genetically defined cancers having GNAQ or GNA11 gene mutations; IDE397, a methionine adenosyltransferase 2a inhibitor that is in Phase 1/2 clinical trials for patients with solid tumors having methylthioadenosine phosphorylase gene deletions, such as non-small cell lung, bladder, gastric, and esophageal cancers; IDE161, a poly ADP-ribose glycohydrolase inhibitor that is in Phase 1 clinical trial to treat tumors with homologous recombination deficiency (HRD), and other genetic or molecular signatures; GSK101, a Pol Theta Helicase inhibitor that is in Phase 1 clinical trial for the treatment of tumors with BRCA or other homologous recombination, and HRD mutations; and Werner Helicase inhibitors for tumors with high microsatellite instability. It offers preclinical research programs focused on pharmacological inhibition; DECIPHER dual CRISPR library for synthetic lethality target and biomarker discovery; and INQUIRE chemical library and HARMONY machine-learning engines to enhance its drug discovery platform. The company has strategic alliances with GlaxoSmithKline, Pfizer Inc., Novartis International Pharmaceuticals Ltd., Amgen Inc., Gilead Sciences, Inc., Cancer Research UK, and the University of Manchester. IDEAYA Biosciences, Inc. was incorporated in 2015 and is headquartered in South San Francisco, California.

Disc Medicine NASDAQ:IRON

$74.12 -1.74 (-2.29%)

Closing price 07/24/2026 04:00 PM Eastern

Extended Trading

$74.10 -0.03 (-0.03%)

As of 07/24/2026 07:34 PM Eastern

Disc Medicine, Inc., together with its subsidiaries, a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases in the United States. The company has assembled a portfolio of clinical and preclinical product candidates that aim to modify fundamental biological pathways associated with the formation and function of red blood cells, primarily heme biosynthesis and iron homeostasis. Its pipeline includes bitopertin for the treatment of erythropoietic porphyrias, including erythropoietic protoporphyria, X-linked protoporphyria, and diamond-blackfan anemia; DISC-0974 for the treatment of anemia of myelofibrosis, and anemia of chronic kidney disease; and DISC-3405 for the treatment of polycythemia vera, and other hematologic disorders. The company's preclinical programs include DISC-0998, for the treatment of anemia associated with inflammatory diseases. Disc Medicine, Inc. was founded in 2017 and is headquartered in Watertown, Massachusetts.

Regencell Bioscience NASDAQ:RGC

$5.72 +0.10 (+1.78%)

Closing price 07/24/2026 04:00 PM Eastern

Extended Trading

$5.70 -0.01 (-0.26%)

As of 07/24/2026 07:34 PM Eastern

Regencell Bioscience Holdings Limited operates a Traditional Chinese medicine (TCM) bioscience company. It focuses on the research, development, and commercialization of TCM for the treatment of neurocognitive disorders and degeneration, primarily attention deficit hyperactivity disorder and autism spectrum disorder. The company was incorporated in 2014 and is headquartered in Causeway Bay, Hong Kong.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest CYRX, IDYA, RGC, and IRON Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest CYRX, IDYA, RGC, and IRON Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

CYRX, IDYA, RGC, and IRON Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

CYRX, IDYA, RGC, and IRON Company Descriptions

CryoPort NASDAQ:CYRX

IDEAYA Biosciences NASDAQ:IDYA

Disc Medicine NASDAQ:IRON

Regencell Bioscience NASDAQ:RGC

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest CYRX, IDYA, RGC, and IRON Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest CYRX, IDYA, RGC, and IRON Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

CYRX, IDYA, RGC, and IRON Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

CYRX, IDYA, RGC, and IRON Company Descriptions

CryoPort NASDAQ:CYRX

IDEAYA Biosciences NASDAQ:IDYA

Disc Medicine NASDAQ:IRON

Regencell Bioscience NASDAQ:RGC

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools